MDGL
VENTE TOTALE: 2 500 titres (~1 356 864,75 $ US)
- Insiders
- Sibold William John
- Total bought
- —
- Total sold
- $1,356,865
- Last activity
- 2026-07-20
- Last synced
-
2026-07-29 15:28:58
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-07-29
MDGL presents a mixed financial picture: adequate liquidity (75) provides near-term runway, but weak fundamental trends (45) reflect persistent cash burn, negative margins, and a materially rising debt-to-equity ratio…
The first sentence of the analysis written for MDGL on 2026-07-29 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 94.1% | 96.5% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | -27.8% | -250.5% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | -27.6% | -249.9% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | -31.3% | -276.4% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | -30.1% | -258.6% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | -30.1% | -258.6% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | -30.1% | -258.6% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | -30.1% | -258.6% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 4.015 | 6.102 | 5.376 | 3.118 | 3.536 | |
| Quick Ratio | 3.774 | 5.901 | 5.376 | 3.118 | 3.536 | |
| Solvency Ratio | -0.437 | -1.615 | -1.586 | -1.785 | -3.126 | |
| Cash Ratio | 0.640 | 0.591 | 0.843 | 2.861 | 0.472 | |
| Price To Earnings Ratio | -45.318 | -14.090 | -11.575 | -16.846 | -5.792 | |
| Price To Earnings Growth Ratio | 1.097 | -1.475 | -0.723 | -0.948 | -0.492 | |
| Forward Price To Earnings Growth Ratio | 1.097 | -1.475 | -0.723 | -0.948 | -0.492 | |
| Price To Book Ratio | 21.677 | 8.701 | 10.668 | 25.199 | 7.145 | |
| Price To Sales Ratio | 13.631 | 36.441 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -68.753 | -14.363 | -13.276 | -22.100 | -7.610 | |
| Price To Operating Cash Flow Ratio | -68.922 | -14.409 | -13.336 | -22.121 | -7.619 | |
| Debt To Assets Ratio | 0.281 | 0.115 | 0.183 | 0.138 | 0.003 | |
| Debt To Equity Ratio | 0.588 | 0.159 | 0.289 | 0.253 | 0.004 | |
| Debt To Capital Ratio | 0.370 | 0.137 | 0.224 | 0.202 | 0.004 | |
| Long Term Debt To Capital Ratio | 0.365 | 0.135 | 0.222 | 0.200 | 0.000 | |
| Financial Leverage Ratio | 2.090 | 1.382 | 1.580 | 1.837 | 1.394 | |
| Working Capital Turnover Ratio | 1.065 | 0.261 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -0.611 | -2.691 | -2.735 | -1.940 | -2.394 | |
| Operating Cash Flow Sales Ratio | -0.198 | -2.529 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | 1.003 | 1.005 | 1.001 | 1.001 | |
| Debt Service Coverage Ratio | -11.337 | -30.681 | -28.350 | -73.390 | 0.000 | |
| Interest Coverage Ratio | -13.452 | -33.936 | -29.932 | -74.059 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -186.201 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.535 | -3.810 | -2.767 | -4.507 | -230.762 | |
| Capital Expenditure Coverage Ratio | -405.895 | -311.609 | -219.222 | -1,036.207 | -879.986 | |
| Dividend Paid And Capex Coverage Ratio | -405.895 | -311.609 | -219.222 | -1,036.207 | -879.986 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -49.987 | -14.626 | -12.046 | -16.130 | -5.657 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 94.1% | ▼-2.4% | ▲56.0% |
| Ebit Margin | -27.8% | ▲222.7% | ▲27.9% |
| Ebitda Margin | -27.6% | ▲222.3% | ▲27.9% |
| Operating Profit Margin | -31.3% | ▲245.1% | ▲30.2% |
| Pretax Profit Margin | -30.1% | ▲228.6% | ▲27.7% |
| Continuous Operations Profit Margin | -30.1% | ▲228.6% | ▲27.7% |
| Net Profit Margin | -30.1% | ▲228.6% | ▲27.7% |
| Bottom Line Profit Margin | -30.1% | ▲228.6% | ▲27.7% |
| Current Ratio | 4.015 | ▼-2.087 | ▼-0.414 |
| Quick Ratio | 3.774 | ▼-2.127 | ▼-0.567 |
| Solvency Ratio | -0.437 | ▲1.178 | ▲1.273 |
| Cash Ratio | 0.640 | ▲0.050 | ▼-0.441 |
| Price To Earnings Ratio | -45.318 | ▼-31.228 | ▼-26.594 |
| Price To Earnings Growth Ratio | 1.097 | ▲2.571 | ▲1.605 |
| Forward Price To Earnings Growth Ratio | 1.097 | ▲2.571 | ▲1.605 |
| Price To Book Ratio | 21.677 | ▲12.975 | ▲6.999 |
| Price To Sales Ratio | 13.631 | ▼-22.809 | ▲3.617 |
| Price To Free Cash Flow Ratio | -68.753 | ▼-54.390 | ▼-43.533 |
| Price To Operating Cash Flow Ratio | -68.922 | ▼-54.513 | ▼-43.641 |
| Debt To Assets Ratio | 0.281 | ▲0.167 | ▲0.137 |
| Debt To Equity Ratio | 0.588 | ▲0.429 | ▲0.330 |
| Debt To Capital Ratio | 0.370 | ▲0.233 | ▲0.183 |
| Long Term Debt To Capital Ratio | 0.365 | ▲0.230 | ▲0.181 |
| Financial Leverage Ratio | 2.090 | ▲0.708 | ▲0.433 |
| Working Capital Turnover Ratio | 1.065 | ▲0.805 | ▲0.800 |
| Operating Cash Flow Ratio | -0.611 | ▲2.080 | ▲1.463 |
| Operating Cash Flow Sales Ratio | -0.198 | ▲2.331 | ▲0.348 |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | ▼-0.001 | -0.000 |
| Debt Service Coverage Ratio | -11.338 | ▲19.344 | ▲17.414 |
| Interest Coverage Ratio | -13.452 | ▲20.484 | ▲16.824 |
| Short Term Operating Cash Flow Coverage Ratio | -186.201 | ▼-186.201 | ▼-148.961 |
| Operating Cash Flow Coverage Ratio | -0.535 | ▲3.275 | ▲47.941 |
| Capital Expenditure Coverage Ratio | -405.895 | ▼-94.286 | ▲164.689 |
| Dividend Paid And Capex Coverage Ratio | -405.895 | ▼-94.286 | ▲164.689 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -49.987 | ▼-35.361 | ▼-30.298 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $13.06B | $6.56B | $4.32B | $4.97B | $1.40B | |
| Enterprise value | $13.22B | $6.58B | $4.34B | $4.69B | $1.37B | |
| EV / Sales | 13.79x | 36.55x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -69.74x | -14.45x | -13.39x | -20.87x | -7.43x | |
| EV / Free cash flow | -69.57x | -14.40x | -13.33x | -20.85x | -7.42x | |
| EV / EBITDA | -49.99x | -14.63x | -12.05x | -16.13x | -5.66x | |
| Net debt / EBITDA | -0.59x | -0.04x | -0.05x | 0.97x | 0.15x | |
| Current ratio | 4.01x | 6.10x | 5.38x | 3.12x | 3.54x | |
| Income quality | 0.66x | 0.98x | 0.87x | 0.76x | 0.76x | |
| Graham net-net | $21 | $33 | $21 | $11 | $12 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 108.4% | 103.3% | 103.5% | 101.4% | 100.0% | |
| Working capital | $935.5M | $863.6M | $518.7M | $245.5M | $194.8M | |
| Invested capital | $949.3M | $873.0M | $522.0M | $246.7M | $196.5M | |
| Return on assets | -22.9% | -44.7% | -58.3% | -81.5% | -88.5% | |
| Operating ROA | -26.1% | -59.2% | -75.9% | -92.3% | -86.6% | |
| Return on tangible assets | -23.0% | -44.9% | -58.3% | -81.5% | -88.5% | |
| Return on equity | -47.8% | -61.8% | -92.2% | -149.6% | -123.3% | |
| Return on invested capital | -31.6% | -57.0% | -72.8% | -118.7% | -123.1% | |
| Return on capital employed | -31.6% | -57.0% | -72.9% | -119.0% | -123.4% | |
| Earnings yield | -2.2% | -7.1% | -8.6% | -5.9% | -17.3% | |
| Free cash flow yield | -1.5% | -7.0% | -7.5% | -4.5% | -13.1% | |
| Capex / Op. cash flow | -0.2% | -0.3% | -0.5% | -0.1% | -0.1% | |
| Capex / Depreciation | 9.9% | 210.1% | 280.6% | 46.5% | 51.6% | |
| Capex / Sales | 0.0% | 0.8% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 84.9% | 241.5% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 40.5% | 131.4% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 10.2% | 44.3% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.6% | 0.5% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 51d | 109d | 0d | 0d | 0d | |
| Days payables outstanding | 318d | 2553d | 0d | 0d | 0d | |
| Operating cycle | 538d | 2104d | 0d | 0d | 0d | |
| Cash conversion cycle | 220d | -449d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+99.0%EV / Sales ▼-62.3%EV / EBITDA ▼-241.8%EV / Op. cash flow ▼-55.292Earnings yield ▲+0.049
Profitability
Return on equity ▲+0.139Return on assets ▲+0.218Return on invested capital ▲+0.254Return on capital employed ▲+0.254Operating ROA ▲+0.331Income quality ▼-0.320Tax burden 0.000
Efficiency
Days sales outstanding ▼-57.844Days payables outstanding ▼-2235.386Operating cycle ▼-1566.325Cash conversion cycle ▲+669.061Capex / Sales ▼-0.008R&D / Sales ▼-0.909
Balance-sheet strength
Current ratio ▼-2.087Net debt / EBITDA ▼-0.545Working capital ▲+71832000.000Invested capital ▲+76331000.000Intangibles / Total assets ▲+0.001
Change over 5 years
Valuation
Market cap ▲+832.4%EV / Sales n/aEV / EBITDA ▼-783.7%EV / Op. cash flow ▼-62.318Earnings yield ▲+0.151
Profitability
Return on equity ▲+0.755Return on assets ▲+0.656Return on invested capital ▲+0.916Return on capital employed ▲+0.918Operating ROA ▲+0.605Income quality ▼-0.103Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.479Net debt / EBITDA ▼-0.736Working capital ▲+740636000.000Invested capital ▲+752807000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2023-04-10 | Daniel Goldman | Sale | $1,001 - $15,000 |
Recent news
- 2026-07-21 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on July 15, 2026 to ten new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-07-16 Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026 CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, prior to the open of the U.S. financial markets.
- 2026-07-13 Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio Received two new U.S. Rezdiffra ® (resmetirom) patents in F2/F3; both patents will be listed in the FDA's Orange Book Received new U.S. resmetirom patent directed to a method of administering resmetirom to treat well-compensated cirrhosis (F4c) CONSHOHOCKEN, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that the United States Patent and Trademark Office (USPTO) issued three new resmetirom patents.
- 2026-07-10 3 Under-the-Radar Stocks to Buy and Hold These three biotechs are posting strong revenue growth. Brand-new launches and label expansions should help them improve their lineups.
- 2026-07-06 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on July 1, 2026 to seven new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-07-02 Ribo y Madrigal alcanzan un primer hito importante en el avance de nuevas terapias con siRNA para MASH /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK) y su filial Ribocure Pharmaceuticals AB (en adelante, "Ribo"), en colaboración con Madrigal
- 2026-07-01 Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH SUZHOU, China and MÖLNDAL, Sweden, July 1, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with Madrigal Pharmaceuticals, Inc. (Madrigal, NASDAQ: MDGL) announce the successful achievement of the first candidate drug nomination milestone within their siRNA partnership.
- 2026-06-22 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on June 15, 2026 to five new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-06-16 3 Under-the-Radar Stocks to Buy and Hold for a Decade All three could become highly prominent biotech companies within 10 years.
- 2026-06-10 Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript